Citadel Advisors’s IDEAYA Biosciences IDYA Stock Holding History

Citadel Advisors’s Portfolio IDYA Stock Details IDYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.62M	Buy	78,500 +59,600	+315%	+$2M	﹤0.01%	5530
2025 Q4	$653K	Buy	+18,900	New	+$603K	﹤0.01%	8365
2025 Q3	–	Sell	-21,000	Closed	-$441K	–	13379
2025 Q2	$441K	Sell	21,000 -9,500	-31%	-$182K	﹤0.01%	8932
2025 Q1	$500K	Buy	30,500 +6,400	+27%	+$136K	﹤0.01%	8478
2024 Q4	$619K	Buy	24,100 +17,400	+260%	+$493K	﹤0.01%	8077
2024 Q3	$212K	Sell	6,700 -1,800	-21%	-$68.3K	﹤0.01%	10021
2024 Q2	$298K	Buy	8,500 +6,000	+240%	+$238K	﹤0.01%	9148
2024 Q1	$110K	Sell	2,500 -1,400	-36%	-$60.2K	﹤0.01%	11226
2023 Q4	$139K	Sell	3,900 -5,600	-59%	-$167K	﹤0.01%	10511
2023 Q3	$256K	Sell	9,500 -200	-2%	-$5.07K	﹤0.01%	9452
2023 Q2	$228K	Buy	+9,700	New	+$199K	﹤0.01%	9594
2023 Q1	–	Sell	-400	Closed	-$7.27K	–	15061
2022 Q4	$7.27K	Buy	+400	New	+$6.73K	﹤0.01%	13836

Other funds holding IDYA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's IDYA Position: Q1 2026 in Review

Citadel Advisors reduced its IDEAYA Biosciences (IDYA) stake by 29% in Q1 2026, selling an estimated $9.39M and leaving 679,400 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2185.

Citadel Advisors first reported a position in IDYA in Q2 2020 and has held it in 19 quarters since. The position peaked at $62.8M in Q1 2024. 253 funds tracked by Wall St. Rank hold IDYA as of Q1 2026.

Citadel Advisors held 679,400 shares of IDEAYA Biosciences worth $22.6M as of Q1 2026.
Citadel Advisors sold 279,955 IDEAYA Biosciences shares in Q1 2026, an estimated $9.39M.
IDEAYA Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2185 holding.
Citadel Advisors first reported a position in IDEAYA Biosciences in Q2 2020 and has held it in 19 quarters since.
Citadel Advisors's IDEAYA Biosciences position peaked at $62.8M in Q1 2024.
253 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.